Unlocking personalised, preventative healthcare

GeneType is transforming healthcare from the one-size-fits-all model to a personalised, preventive approach.

By developing the next generation of integrated predictive genetic testing and assessment tools, we are empowering healthcare professionals and their patients to proactively manage health.

The Science

Our patented technology sets us apart

Patents granted in US
  • Patent 11,031,098, Computer systems and methods for genomic analysis
  • Patent 10,683,549, Methods for assessing risk of developing breast cancer
  • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk assessment test
  • Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk assessment alone)
  • Patent No. 6,969,589 covering the identification of informative SNPs
Patents granted in China
  • Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0 “Markers for Breast Cancer”
  • Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment
  • Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast Cancer”
  • Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment
Patent families pending
  • Methods for breast cancer risk assessment
  • Methods for assessing risk of developing breast cancer
  • Improved methods for assessing risk of developing breast cancer
  • Markers for breast cancer
  • Methods for genetic analysis
  • Methods for genomic analysis
  • Methods for assessing risk of developing colorectal cancer
  • Methods of assessing risk developing a disease
  • Methods for assessing risk of developing a severe response to coronavirus infection

Keep up-to-date with our latest advances

Sign up to our newsletter to stay informed about our latest advances and how these could support you.